SCHEMBL1480976

SCHEMBL1480976

CCn1cc(-c2cccc(C(F)(F)F)c2)nc1/C=C/c1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.47
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
KDR P35968 1/20 0.39
TEK Q02763 1/20 0.39
ADORA2A P29274 1/20 0.39
F2RL3 Q96RI0 1/20 0.39
ERBB2 P04626 2/20 0.38
TRPM2 O94759 1/20 0.38
NFE2L2 Q16236 1/20 0.38
CNR2 P34972 4/20 0.38
GFER P55789 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
GPR55 Q9Y2T6 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480980 1.00 TLR8 (0.47) TLR8ESR1ESR2KDRTEK
SCHEMBL1481256 0.88 GFER (0.46) TLR8ERBB2GFERMEN1KMT2A
SCHEMBL1481259 0.88 GFER (0.46) TLR8ERBB2GFERMEN1KMT2A
SCHEMBL1480797 0.87 TLR8 (0.49) TLR8ADORA2AF2RL3ERBB2NFE2L2
SCHEMBL1480800 0.87 TLR8 (0.49) TLR8ADORA2AF2RL3ERBB2NFE2L2
SCHEMBL1481248 0.87 MEN1 (0.45) ESR1GFERMEN1KMT2AKDM4E
SCHEMBL1481245 0.87 MEN1 (0.45) ESR1GFERMEN1KMT2AKDM4E
SCHEMBL1482187 0.84 MEN1 (0.48) TLR8GFERMEN1KMT2AKDM4E
SCHEMBL1482183 0.84 MEN1 (0.48) TLR8GFERMEN1KMT2AKDM4E
SCHEMBL1481360 0.82 PPARA (0.42) TLR8ESR1ESR2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ TLR8 2695/4885ESR1 3406/4885ESR2 2824/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ TLR8 2695/4885ESR1 3406/4885ESR2 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.